Anthrax Letters Investigation Reveals Persistent Gaps in Biothreat Detection and Response

The CDC's Epidemiology and Surveillance Team documented distinct clinical patterns between the September and October mailings. The first batch produced mostly cutaneous cases from clumped spores in media offices, while the second yielded more inhalational anthrax among postal workers exposed to finer, aerosolizable powder. Molecular typing confirmed a single Ames strain source across patients, envelopes, and environments, but pre-attack guidance on resuspension risk proved inadequate after multiple postal worker fatalities. This forced rapid revision of prophylaxis protocols beyond direct envelope handlers. Twenty-five years later, AI-driven biothreat surveillance and expanded Laboratory Response Network capacity exist, yet real-world testing of aerosol dynamics in modern mail systems remains limited. No intentional anthrax releases have occurred since, but white-powder incidents continue to strain resources without corresponding investment in predictive modeling of formulation effects on clinical outcomes.